pufa 22:5 n-3 (dpa)

PUFA 22:5 n‑3, commonly known as docosapentaenoic acid (DPA), is a long‑chain omega‑3 polyunsaturated fatty acid. Chemically, it contains 22 carbon atoms and five cis double bonds with the first double bond at the third carbon from the methyl end of the molecule, which classifies it as an n‑3 or omega‑3 fatty acid. DPA is structurally similar to the more widely studied omega‑3 fatty acids EPA (eicosapentaenoic acid, 20:5n‑3) and DHA (docosahexaenoic acid, 22:6n‑3) and sits metabolically between them in the human body’s elongation and desaturation pathways. Humans derive DPA from dietary sources, particularly cold‑water oily fish and certain meats, and it also can be synthesized in small amounts from EPA via elongase enzymes. In addition to its presence in dietary foods, DPA can be carried in plasma and incorporated into cellular membranes, where it contributes to membrane fluidity and is available for conversion into bioactive lipid mediators. Although research on DPA specifically has historically been limited compared to EPA and DHA, appreciation for its unique physiologic roles has grown. DPA is an intermediary in the metabolic pathway linking EPA to DHA and can also be retroconverted back to EPA in tissues, suggesting a dynamic role in maintaining omega‑3 balance. Metabolites derived from DPA, including specialized proresolving mediators (SPMs) such as resolvins, protectins, and maresins, are increasingly recognized for their roles in inflammation resolution and cell signaling. These metabolites are distinct from those produced by EPA and DHA, which indicates that DPA may exert distinct benefits within the broader spectrum of omega‑3 fatty acids. In nutrition research, DPA is noted as a minor constituent of total serum unsaturated fatty acids in humans but may increase with changes in diet or supplementation. Because humans cannot interconvert omega‑3 and omega‑6 classes, dietary intake of DPA, along with other long‑chain omega‑3s, contributes to the overall balance of fatty acids necessary for health. Given its structural properties and metabolic relationships, DPA plays roles in maintaining cell function, signaling, and potentially health outcomes, though the depth of evidence specific to DPA continues to evolve.

DPA participates in multiple physiological processes, primarily through its role as part of the omega‑3 polyunsaturated fatty acid family. One of the well‑described functions of omega‑3 PUFAs, including DPA, is their incorporation into cell membranes, which influences membrane fluidity and receptor function. This structural role can modulate signaling pathways related to inflammation, blood vessel dilation, and cellular responses to stress. In addition, DPA serves as a precursor for specialized proresolving mediators (SPMs), including specific resolvins, protectins, and maresins. These metabolites help regulate the resolution phase of inflammation, distinguishing them from classic pro‑inflammatory eicosanoids, and have been implicated in cardiovascular protection and immune modulation. Cardiovascular health is one area where long‑chain omega‑3 PUFAs including DPA have been studied. Though most clinical evidence centers on EPA and DHA, observational data suggest that higher combined levels of omega‑3 PUFAs, including DPA, are associated with lower risk of fatal cardiac events and improved risk profiles for nonfatal cardiovascular endpoints. Mechanistically, omega‑3 PUFAs can reduce triglyceride levels, support endothelial function, and modulate platelet aggregation. Small studies indicate that DPA may inhibit platelet aggregation and influence lipid metabolism, potentially offering anti‑thrombotic effects. In vitro and animal studies hint at greater inhibition of platelet aggregation by DPA compared to EPA. Beyond cardiovascular effects, omega‑3 PUFAs contribute to neurological development and function. DHA is particularly concentrated in brain and retinal tissues; however, DPA and EPA may also support neural cell health indirectly through anti‑inflammatory pathways. In infancy, human breast milk contains appreciable amounts of DPA along with DHA, highlighting its role in early brain and visual system development. Some animal studies propose that DPA supplementation may attenuate age‑related cognitive decline and influence gene expression relevant to neural plasticity. Emerging evidence also supports roles for DPA in metabolic regulation. For example, DPA may influence lipid oxidation and lipogenesis, favorably shifting energy metabolism via effects on lipid enzymes. Other potential benefits under investigation include modulation of immune responses, attenuation of inflammatory bowel disease models, and effects on skin and wound healing. While the bulk of robust clinical evidence focuses on EPA and DHA, these observations point toward unique and overlapping contributions of DPA to health outcomes. Continued research, including randomized controlled trials specifically assessing DPA intake and health effects, is needed to clarify optimal intake levels and mechanistic pathways attributable to this specific omega‑3 fatty acid.

Unlike nutrients such as vitamins and minerals that have established recommended dietary allowances (RDAs) set by authoritative bodies, there are no specific RDAs or Adequate Intakes defined for docosapentaenoic acid (DPA) alone. Major health agencies, including the NIH Office of Dietary Supplements, do not list DPA as a separate nutrient with unique intake recommendations; instead, guidelines focus on total long‑chain omega‑3 fatty acids, especially EPA and DHA, given the stronger evidence base for these compounds. As a practical matter, dietary intake of DPA is subsumed within recommendations for total omega‑3 PUFA consumption. For general health and cardiovascular benefits, many organizations suggest consuming approximately 250–500 milligrams per day of combined EPA and DHA for healthy adults. In the context of daily omega‑3 intake, DPA contributes to this pool when present in seafood and other food sources. Some experts suggest that getting about 1–1.5 grams of total omega‑3 fatty acids (ALA, EPA, DHA, including DPA) daily through diet may support overall health. Regulatory bodies like the FDA have indicated that up to about 5 grams per day of combined EPA and DHA is typically considered safe in adults, but this upper boundary addresses combined intake and does not isolate DPA. For individuals with specific health conditions, such as elevated triglycerides or cardiovascular disease, higher intakes of EPA/DHA (and by extension total long‑chain omega‑3s) may be recommended under clinical guidance. Factors influencing individual needs for omega‑3 fatty acids include age, sex, physiological state (such as pregnancy and lactation), genetic factors affecting fatty acid metabolism, and overall dietary patterns. For example, during pregnancy and early life, adequate omega‑3 intake is important for neural and visual development, with some guidelines recommending higher intakes of EPA and DHA. Although DPA’s specific role during pregnancy is less well defined, it forms part of the total long‑chain omega‑3 pool available to the developing fetus and infant. In older adults and those with chronic inflammatory conditions, incorporating omega‑3–rich foods may help modulate inflammation over time. Because DPA can interconvert with EPA and be metabolically related to DHA, ensuring a diet rich in a variety of long‑chain omega‑3 sources will naturally provide DPA alongside EPA and DHA. Key dietary contributors include fish and seafood, which deliver all three long‑chain omega‑3 fatty acids in varying proportions. In practice, achieving recommended omega‑3 intakes involves eating fatty fish at least twice weekly or consulting a healthcare provider about supplements, especially for those who do not regularly consume seafood. Given that population intake of long‑chain omega‑3s in Western diets often falls below recommended levels, emphasizing diverse dietary sources and considering individual nutritional needs are important for optimizing health outcomes.

Because docosapentaenoic acid (DPA) is one component of the broader family of omega‑3 polyunsaturated fatty acids and because formal deficiency criteria for DPA specifically do not exist in authoritative nutrition guidelines, isolated DPA deficiency is not a clinically defined condition. Instead, clinical deficiency syndromes are associated with a broader lack of essential omega‑3 fatty acids, especially EPA and DHA. Essential fatty acids are critical for cell membrane integrity, neural development, and inflammatory regulation, and their absence manifests with characteristic physiologic disruptions. In the absence of sufficient long‑chain omega‑3 intake, individuals may exhibit signs reflecting impaired structural and metabolic functions dependent on these fatty acids. Common signs associated with chronic low intake of long‑chain omega‑3 fatty acids include dry, scaly skin, dermatitis, brittle hair and nails, impaired wound healing, and excessive thirst. These cutaneous symptoms often reflect disrupted cell membrane integrity and inflammatory imbalances that rely on omega‑3–derived bioactive mediators for resolution. In addition, individuals with insufficient omega‑3 status may experience mood disturbances, fatigue, and cognitive symptoms, although these are nonspecific and can overlap with other nutrient deficiencies. Neurologically, inadequate omega‑3 status during critical developmental periods, such as infancy and childhood, may be linked to suboptimal visual acuity and cognitive outcomes, mirroring the importance of these fats in neural tissue composition. Individuals at higher risk for low omega‑3 status include those with limited intake of fish and seafood, strict vegetarians or vegans without supplemental long‑chain omega‑3 sources, and populations with increased metabolic demands, such as pregnant and lactating individuals. Clinical observations suggest that populations consuming Western diets high in omega‑6 fatty acids and low in omega‑3s may present with a relative imbalance that exacerbates pro‑inflammatory states. Although specific prevalence data for isolated DPA deficiency are not established, low plasma levels of DPA and other long‑chain omega‑3s are common in cohorts with low seafood intake. Healthcare practitioners measure fatty acid status using blood lipid panels that include EPA, DHA, and sometimes total omega‑3 indices. There is emerging interest in assessing DPA as part of comprehensive omega‑3 profiling, with some laboratories reporting optimal DPA proportions within a range where total omega‑3 indices exceed recommended thresholds. Reported values for individual DPA proportions in plasma phospholipids often range between 0.3 % and 5 % of total fatty acids in healthy adults, though specific optimal thresholds are still under research. Conversion dynamics between DPA, EPA, and DHA further complicate isolated deficiency assessments because low levels of one may reflect insufficient intake or altered metabolism of others. Clinically, achieving balanced intake of all long‑chain ovarian omega‑3s through diet and, if necessary, supplementation is the mainstay of preventing deficiency syndromes attributed to a broader lack of essential fatty acids.

Docosapentaenoic acid (DPA) is most abundant in foods that are rich in long‑chain omega‑3 fatty acids, particularly marine sources and some ruminant meats. The USDA and other nutrient databases list several high‑DPA foods, with fish oils and fatty fish at the top of the list. For example, menhaden oil and salmon oil provide significant DPA per serving, followed by cooked wild salmon, Pacific herring, and other fish species. These foods not only supply DPA but also deliver EPA and DHA, contributing to overall beneficial omega‑3 intake. Oily fish such as salmon, herring, mackerel, tuna, and sardines consistently supply the highest levels of DPA, along with EPA and DHA. A three‑ounce serving of cooked wild Atlantic salmon can provide approximately 0.626 grams (626 mg) of DPA, making it one of the richest natural food sources. Pacific herring and cooked bluefin tuna also rank high in DPA content per serving. Other fish species like tilefish, sablefish, and whitefish contribute lower but still meaningful amounts. Fish oils, including menhaden and salmon oil, concentrate omega‑3s, delivering gram‑level quantities of DPA per tablespoon, though intake through whole foods is generally promoted for broader nutritional benefits. Beyond fish, lean red meats, especially grass‑fed beef, and certain offal such as lamb brain also contain DPA, albeit in smaller quantities compared to oily fish. Ruminant meat provides a dietary source of DPA that may contribute to total omega‑3 status, particularly for individuals who consume little seafood. Additionally, although plant sources like flaxseed, chia seeds, and walnuts are rich in alpha‑linolenic acid (ALA), the precursor to long‑chain omega‑3s, conversion of ALA to DPA, EPA, and DHA in humans is inefficient. Therefore, while plant sources support overall omega‑3 status, they do not directly supply preformed DPA. Understanding food sources of DPA also involves considering preparation methods. For example, cooking methods that preserve oils, such as baking or steaming, tend to retain higher levels of omega‑3 fatty acids compared to frying, which can degrade these fats due to heat and oxidation. Eating a variety of seafood species ensures a broader intake of DPA along with other essential fatty acids and nutrients, including high‑quality protein, vitamins, and trace minerals. Dietary patterns that incorporate fish twice per week, emphasizing fatty fish, align with general omega‑3 intake recommendations and naturally include DPA. When whole food sources are insufficient to meet omega‑3 needs, supplements like fish oil, krill oil, and algal oil may help augment intake. However, supplement formulations vary in their ratios of EPA, DHA, and DPA, and not all products emphasize DPA content specifically. Therefore, reviewing supplement labels and consulting a healthcare provider can help tailor intake to individual nutritional goals and health conditions. Overall, food sources rich in DPA also contribute to a heart‑healthy dietary pattern that supports inflammatory balance and cell membrane function.

Absorption of docosapentaenoic acid (DPA) occurs through the same pathways that handle other long‑chain omega‑3 fatty acids. Dietary fats, including DPA, are emulsified by bile salts in the small intestine, forming micelles that facilitate uptake by enterocytes. Within enterocytes, DPA is incorporated into chylomicrons, lipoprotein particles that transport dietary lipids through the lymphatic system into circulation. Because DPA is a long‑chain fatty acid, its incorporation into micelles and subsequent absorption depend on adequate bile production and pancreatic enzyme activity. Individuals with fat malabsorption conditions, such as pancreatic insufficiency, cholestasis, or celiac disease, may have reduced absorption of long‑chain fatty acids, including DPA. Bioavailability of DPA also relates to its dietary matrix and form. Fats consumed as part of whole foods, such as oily fish, are typically well‑absorbed compared to isolated supplements taken without food. Consuming DPA with a meal that contains other fats enhances micelle formation and promotes uptake. Conversely, taking DPA supplements on an empty stomach may result in less efficient absorption. Additionally, the presence of certain nutrients and dietary factors influences bioavailability: antioxidants like vitamin E help protect polyunsaturated fats from oxidative damage in the gut, preserving their structure for absorption. High intake of phytosterols or soluble fibers may slightly reduce absorption of dietary fats, although the clinical significance for DPA specifically is minimal. The metabolic fate of DPA after absorption involves incorporation into plasma phospholipids and triglycerides, where it can contribute to circulating fatty acid pools. DPA may be retroconverted to EPA or elongated and desaturated further, albeit at limited rates. Some evidence suggests that DPA levels in plasma phospholipids reflect dietary intake and can influence the overall omega‑3 index, a marker of long‑chain omega‑3 status. Because DPA shares metabolic pathways with EPA and DHA, overall omega‑3 status and dietary patterns influence how effectively DPA is utilized. Factors such as age, genetics, and health status (e.g., presence of chronic inflammation) modulate enzymes involved in elongation, desaturation, and incorporation. Timing of intake can also affect bioavailability. Splitting omega‑3 intake across meals may help sustain steady plasma levels, whereas large single doses may be less efficiently utilized. For individuals with compromised digestion, combining DPA intake with digestive enzymes or ensuring adequate bile flow can enhance utilization. Overall, DPA is well‑absorbed in the context of a balanced diet containing sufficient fats, and its bioavailability is supported by the same physiological mechanisms that handle other long‑chain omega‑3 fatty acids.

People considering supplements specifically for docosapentaenoic acid (DPA) should first evaluate their overall omega‑3 intake and individual health goals. While DPA is a component of certain fish oils and omega‑3 supplements, most products emphasize EPA and DHA because these have a stronger evidence base for cardiovascular and neurological health outcomes. Pure DPA supplements are less common, and clinical studies specifically examining isolated DPA supplementation in humans are limited. Nonetheless, some research indicates that DPA may support cardiovascular health, modulate platelet aggregation, and influence lipid metabolism, suggesting potential benefits when included as part of a comprehensive omega‑3 regimen. For individuals with low dietary intake of oily fish or seafood, taking a high‑quality omega‑3 supplement that includes DPA alongside EPA and DHA may help ensure balanced long‑chain omega‑3 status. Supplements derived from fish oil, krill oil, and, less commonly, algae oil can contribute to total EPA/DHA/DPA intake. In choosing a supplement, consumers should review the fatty acid profile to understand the proportions of each omega‑3 fatty acid. Products that list DPA explicitly may be beneficial for those seeking its potential unique effects, though evidence supporting its specific clinical utility remains emerging. Individuals with hypertriglyceridemia may benefit from higher doses of long‑chain omega‑3 supplements, often under medical guidance, as recommended for reducing triglycerides; these regimens typically use concentrated EPA and DHA formulations, but DPA presence may provide additional benefit given its mechanistic roles in lipid metabolism. When contemplating supplementation, safety and quality considerations are paramount. Supplements should be sourced from reputable manufacturers and independently tested for purity, potency, and contaminants such as mercury or PCBs. Certifications from third‑party organizations like USP or NSF provide assurance of quality. People with certain health conditions, such as bleeding disorders or those taking anticoagulant medications, should consult healthcare professionals before starting omega‑3 supplements, as high doses can influence bleeding risk. Timing and dosing strategies may vary based on individual needs; taking omega‑3 supplements with meals enhances absorption and reduces gastrointestinal discomfort. Overall, while direct evidence for DPA‑specific supplementation is growing, current guidance emphasizes achieving adequate total long‑chain omega‑3 intake through diet and supplements focusing on EPA and DHA. Including DPA as part of this broader omega‑3 strategy may offer additional physiological advantages, but individuals should tailor their approach based on dietary patterns, health conditions, and professional medical advice.

Isolated docosapentaenoic acid (DPA) toxicity is not well defined because no authoritative tolerable upper intake level (UL) has been established specifically for DPA. Regulatory guidance for omega‑3 fatty acids generally focuses on combined EPA and DHA intakes, with the FDA advising that up to about 5 grams per day of EPA+DHA is typically safe for most adults. While DPA is part of the broader omega‑3 pool and would be included in such totals when present in fish oil or marine supplements, toxic effects attributed solely to DPA have not been documented. Excessive intake of long‑chain omega‑3 fatty acids, in general, can lead to a range of physiological effects, primarily related to their influence on bleeding risk and immune responses. High intakes of omega‑3s may prolong bleeding time and interact with platelet function, which could increase the risk of hemorrhage, especially in people taking anticoagulant or antiplatelet medications or those with bleeding disorders. At very high doses, omega‑3 supplements have been associated with gastrointestinal adverse effects such as nausea, diarrhea, and fishy aftertaste. Rarely, individuals may develop allergic reactions to fish or seafood‑derived supplements. Concerns about contaminants, including mercury, PCBs, and other toxins in fish oil products, underscore the importance of choosing purified, third‑party–tested supplements. Because DPA often coexists with EPA and DHA in natural oils, ensuring that combined intake does not exceed recommended limits helps minimize potential risks. For individuals using concentrated fish oil products or taking multiple supplements containing omega‑3s, cumulative intake should be monitored to avoid surpassing established safety guidelines. Additionally, evidence suggests that very high doses of omega‑3s may affect immune function, potentially diminishing inflammatory responses that are beneficial in certain contexts. While some immunomodulation is therapeutic, blunting necessary inflammatory responses could impair infection defense. Given the lack of specific toxicity data for DPA, applying general omega‑3 safety principles helps guide safe intake. People with underlying health conditions, pregnant or breastfeeding individuals, and those taking medications should seek professional guidance before consuming high doses of omega‑3 supplements. Maintaining a balanced diet with food sources of omega‑3s, combined with appropriate supplement use when needed, supports health while minimizing risk.

Docosapentaenoic acid (DPA) is metabolically related to other long‑chain omega‑3 fatty acids and shares similar interaction profiles when consumed at moderate to high doses as part of fish oil or marine lipid supplements. One of the most clinically relevant interactions involves blood‑thinning medications, including warfarin, aspirin, clopidogrel, and other antiplatelet or anticoagulant drugs. Omega‑3 fatty acids, including DPA, can influence platelet aggregation and blood viscosity, potentially enhancing the effects of these medications and increasing bleeding risk. People taking anticoagulants should consult with a healthcare provider before starting or increasing omega‑3 supplementation and may require monitoring of coagulation parameters. In addition to anticoagulant interactions, high intake of long‑chain omega‑3s may interact with antihypertensive medications. Omega‑3 fatty acids can modestly lower blood pressure, which may complement the action of antihypertensives but could require dose adjustments in sensitive individuals to avoid hypotension. Additionally, omega‑3 supplements may affect immune responses, potentially influencing the efficacy of immunosuppressive therapies in people with autoimmune conditions or organ transplants; such interactions are complex and should be managed by clinicians. Although interactions specifically attributable to DPA alone have not been extensively studied, its inclusion in supplements containing EPA and DHA suggests that similar precautions apply. People using lipid‑lowering medications, such as statins or fibrates, may benefit from combined therapy with omega‑3 fatty acids for triglyceride reduction, but healthcare providers should tailor regimens based on individual cardiovascular risk profiles. Overall, communication between patients and clinicians about supplement use and medication regimens helps mitigate interaction risks and optimize therapeutic outcomes.

Common Forms: Fish oil capsules, Krill oil, Algal oil general omega‑3

Typical Doses: Total long‑chain omega‑3 ~250–500 mg/day; higher doses for specific conditions as advised

When to Take: With meals to enhance absorption

Best Form: Triglyceride or phospholipid‑based omega‑3 supplements with meals

⚠️ Interactions: Warfarin, Antiplatelet medications, Antihypertensive drugs